Blood markers to better sort who needs urgent colorectal testing
Official title: Plasma Biomarkers in Stratifying Patients Referred Via the Lower Gastro-intestinal (LGI) Suspected Cancer Two-week Wait (2WW) Pathway
Run by Queen Mary University of London · NCT07035691 · Data updated 2026-11-12
This will test whether a blood test measuring hPG80 and mobile genetic elements can spot colorectal cancer or polyps in adults referred for urgent bowel investigations.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 582 (estimated) |
| Sponsor | Queen Mary University of London Academic / other |
| Locations | 1 site (London, England) |
| Status | Recruiting |
| Started | June 30, 2025 |
| Main results expected | August 31, 2027 |
| Study ends | August 31, 2027 |
| Registry record updated | September 8, 2026 |
| Trial ID | NCT07035691 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults over 18 referred to the 2WW or STT pathway for suspected lower GI cancer who can give consent, are fit for standard investigations, and do not have inflammatory bowel disease or documented familial colorectal cancer.
✕Probably not a fit
Patients referred outside the 2WW/STT pathways (including emergency referrals), those with untreated solid organ cancers, known inflammatory bowel disease, or familial CRC are unlikely to benefit from this approach.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational project will collect a 20 ml blood sample from adults referred to the two‑week‑wait (2WW) or Straight to Test (STT) pathway for suspected lower gastrointestinal cancer. Plasma will be analyzed for circulating progastrin (hPG80) levels and signatures of transposable elements (TEs), and results will be compared with findings from routine diagnostic investigations such as colonoscopy, CT colonography, and FIT. Participants will receive standard clinical care and their final clinical diagnosis will serve as the reference standard for biomarker performance. The project will also record patient preferences for a blood-based test versus more invasive diagnostic methods to inform acceptability and potential implementation.
Why it matters
Potential benefit: If successful, the blood test could reduce unnecessary invasive procedures and help prioritize patients who most need urgent colonoscopy.
How similar studies have gone: Prior work has reported higher hPG80 and altered TE signals in colorectal cancer and some polyps, but combining these markers and applying them prospectively in the 2WW/STT referral population is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult, lower GI 2WW and or Straight to Test (STT) referral patients with suspected lower GI cancer. * Male and Female patients aged \>18 years. * 2WW referral patients with no history of inflammatory bowel disease. * Performance status (ECOG 0-2; and 3 pending clinical assessment of fitness). * Patients with capacity to consent to the study. Exclusion Criteria: * Any patients referred outside of the 2WW and or STT referral pathways with suspected Lower GI cancer or those referred as an emergency with or suspected CRC. * Age \< 18 years. * Patients not fit for standard investigations (e.g. not fit for gastroscopy, colonoscopy or CT colonography) in the 2WW pathway. * Patients with no capacity to consent or who declined consent for participation. * Patients with untreated solid organ cancers. * Patients with known inflammatory bowel disease. * Patients with documented familial type CRC.
Where it's running
-
Barts Health NHS Trust
London, England, United Kingdom Recruiting
Study contacts
- Principal investigator: Mohamed A Thaha, MBBS, FRCS, PhD, PGCe Hlt Econ — Queen Mary University of London
- Study coordinator: Valentin Butnari, MBBS, MSc
- Email: v.butnari@qmul.ac.uk
- Phone: +442078828747
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Exercise after pelvic radiation to see if it lowers colorectal cancer risk
This study tests whether regular walking therapy after pelvic radiation for prostate cancer can influence markers of colorectal cancer in colon tissue and blood.
-
Irreversible Electroporation for Recurrent Pelvic Tumors
This study tests whether using irreversible electroporation (IRE) is safe and helps control recurrent pelvic tumors in adults who can’t have other local treatments.
-
Smart Symptom Tracking with ALEX for GI Health in Young Adults
This trial tests whether the Smart Symptom Tracking ALEX app can better track GI symptoms in young adults (18–44) compared with standard paper logs.
-
Culturally adapted online genetic counseling and testing education for African American cancer survivors
We will test a culturally adapted online genetic counseling program to see if it increases genetic counseling and genetic testing among African American breast, prostate, and colorectal cancer survivors.
-
Zanidatamab given before surgery for HER2-positive colon or rectal cancer
This tests whether giving zanidatamab before surgery helps adults with HER2-positive, RAS‑wildtype colon or rectal cancer who are planned for curative treatment.
-
In-home cancer treatment with remote specialist support for patients in the Florida Panhandle
This program will try giving standard cancer treatments at home to people living in the Florida Panhandle and nearby areas to see if they prefer it and have better treatment satisfaction.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.